Shilpa Medicare's strategic partnerships and collaborations with leading pharmaceutical companies worldwide, driving innovation in biologics, vaccines, and specialized therapeutics.
Shilpa Medicare has established strategic partnerships with leading pharmaceutical companies worldwide to advance innovation in biologics, vaccines, and specialized therapeutics. These collaborations leverage our world-class R&D infrastructure, GMP manufacturing capabilities, and regulatory expertise to bring cutting-edge treatments to patients globally.
Licensed supply and marketing agreement for Adalimumab in India, bringing affordable biosimilar therapy to Indian patients with autoimmune disorders.
Co-development and commercialization of novel immuno-oncology assets. Shilpa provides GMP development and manufacturing expertise for cutting-edge cancer therapeutics.
Strategic agreement for manufacturing and supply of Sputnik V vaccine via Shilpa Biologicals, supporting India's COVID-19 vaccination program.
Agreement to commercialize recombinant human albumin in Europe. Orion will distribute while Shilpa supplies this critical therapeutic protein.
Shilpa is acting as lead investor in Alveolus Bio, a biotechnology company focused on respiratory therapeutics. This strategic investment demonstrates our commitment to expanding into emerging therapeutic areas and supporting innovative biotech companies.
Our partnership strategy is built on mutual value creation, combining Shilpa's manufacturing excellence with our partners' market access and therapeutic expertise.
Novel cancer immunotherapy assets and biosimilars
Adalimumab and other monoclonal antibody biosimilars
COVID-19 vaccines and other preventive biologics
Investment in respiratory therapeutic innovations
We welcome discussions with pharmaceutical companies, biotech firms, and research organizations interested in strategic collaborations. Our flexible partnership models and proven track record make us an ideal partner for companies looking to:
Interested in partnering with Shilpa Medicare?
Contact our Business Development team to explore collaboration opportunities
